While cervical cancer was once a leading cause of cancer death, the combined efforts of increased education, screening, research, and prevention methods have significantly reduced its impact among women worldwide.
Still, according to the Canadian Cancer Society (CCS), an estimated 1,450 women were diagnosed with cervical cancer in 2022, with 380 deaths among them.
In Canada, cervical cancer accounts for approximately 2 percent of new cancers in women, with 67 percent of these occurring in women between 30 and59. Over the last few decades, the incidence rates of cervical cancer have decreased steadily, with increased awareness, screening, and testing the likely reason.
Cervical cancer research has already led to several breakthroughs in prevention and treatment.
The American Association for Cancer Research reports that various new immunotherapeutic strategies (for example, the recently approved checkpoint inhibitor pembrolizumab [Keytruda]) are being used in the successful treatment of cervical cancer.
A Lancet Oncology modeling study also indicates that the continued spread of cervical cancer screening and availability of HPV vaccines could prevent approximately 13 million global cases of cervical cancer by 2069.
Regular cervical cancer screenings are paramount for early detection, leading to the best preventative and treatment efforts. According to the Canadian Cancer Society, there are two screening options patients should be aware of:
The best preventative remedy for cervical cancer is the HPV vaccine.
Health Canada recommends that girls and women between the ages of 9 and 27 receive the vaccine. It may also be administered to those 27 and older who have an ongoing risk of exposure.
The Canadian government has approved three HPV vaccines:
It is also important to remind patients to continue getting regular screenings, even if they have received the vaccine.
Despite increased awareness and access to screening in recent years, various barriers to testing continue to prevent thousands of women from being screened for cervical cancer.
A recent systematic review of various studies revealed three primary categories of barriers and challenges to cervical cancer screening (CCS):
72.2 percent of reviewed studies reported that lack of knowledge or awareness of cervical cancer screening/prevention was a leading barrier to women opting for regular tests. Lack of physician recommendation and participants’ health literacy gaps are contributing factors.
Another common set of barriers to regular CCS is socio-cultural and psychological. A large number of young people appear resistant to testing due to factors like:
Additionally, “the fear of finding cancer” is another major psychological barrier in this group.
Systemic, economic, and practical barriers are the final category of reasons why young women ignore or delay testing.
The cost of testing is a significant factor, especially among women without healthcare insurance. Other factors preventing regular CCS are:
OncologyEducation provides updated, peer-reviewed resources and research to thousands of global oncology professionals, connecting a worldwide network of leading scientists, healthcare professionals, students, and researchers.
For the latest news and research in oncology, register today and join the OncologyEducation community to stay updated.
OncologyEducation and MDBriefCase are members of the Think Research family of companies.
199 Bay Street #4000, Toronto,
ON M5L 1A9
In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Academy website (the “Website”), you (“You”) expressly agree to the following:
Review: MDBriefCase is pleased to consider the publication of Your Work on the Website. The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.
Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered. If posted, You will be identified as the author of the Work, or co-author if applicable.
Grant of Rights: As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats: (1) the exclusive right of first publication worldwide; (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications. The grant of rights survives termination or expiration of this Agreement.
Warranty: You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work. This warranty survives termination or expiration of this Agreement.
Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Academy website.
The Healthcare Leadership Academy welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished. When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.
Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.
Guest articles for the MDBriefCase Healthcare Leadership Academy may run between 500 and 1000 words.
MDBriefCase reserves the right to accept or reject any submission and the right to condition acceptance upon revision of material to conform to its criteria.
There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal websites, corporate websites and social media platforms.
Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement.
